Titan Pharmaceuticals Inc (TTNP)

[rikshot]

More rhetoric to keep the doors open a little longer: Proneura is not a drug & JT-09 is supposed to stop "itching".
---------------------------------------------------------------------------
Biotech Penny Stocks to Watch: Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc. ( TTNP Stock Report ) is a biotech penny stock that shot up by almost 28% by EOD on November 10th. At the beginning of the month, the company announced that it had completed an agreement to settle its debt with Molteni and Horizon Credit. In addition, the company announced that it had agreed to acquire JT Pharmaceutical Inc’s drug known as JT-09 for use in combination with its drug ProNeura.

[Read More] 4 Penny Stocks To Buy According To These Analysts; Do You Agree?

The executive chairman of the company, Dr. Marc Rubin stated that “as a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan’s assets, including all the ProNeura intellectual property. With the net proceeds from our recent public offering, a significant reduction in operating expenses, and full ability to capitalize on our IP, we are well-positioned to progress.”

Based out of California, Titan Pharmaceuticals has been working to develop its ProNeura drug to treat a wide range of chronic conditions. With shares at only $0.14 as of November 10th, it looks like TTNP stock has a low barrier to entry for investors. All things considered, it continues to look like an intriguing biotech penny stock to watch.